Moreover, O’Brien et al. treated 90 patients in early CML-CP with the triple combination of HHT, IFN-a, and low-dose ara-C, which yielded a 94% CHR and a 74% CyR, including 22% CCyR. This evidence concerns the gene IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive.